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Objective: Neuronal loss in the substantia nigra pars compacta (SNpc) in Parkinson disease (PD) is not uniform, as
dopamine neurons from the ventral tier are lost more rapidly than those of the dorsal tier. Identifying the intrinsic dif-
ferences that account for this differential vulnerability may provide a key for developing new treatments for PD.
Methods: Here, we compared the RNA-sequenced transcriptomes of ~100 laser captured microdissected SNpc neu-
rons from each tier from 7 healthy controls.
Results: Expression levels of dopaminergic markers were similar across the tiers, whereas markers specific to the neigh-
boring ventral tegmental area were virtually undetected. After accounting for unwanted sources of variation, we identi-
fied 106 differentially expressed genes (DEGs) between the SNpc tiers. The genes higher in the dorsal/resistant SNpc
tier neurons displayed coordinated patterns of expression across the human brain, their protein products had more
interactions than expected by chance, and they demonstrated evidence of functional convergence. No significant
shared functionality was found for genes higher in the ventral/vulnerable SNpc tier. Surprisingly but importantly, none
of the identified DEGs was among the familial PD genes or genome-wide associated loci. Finally, we found some DEGs
in opposite tier orientation between human and analogous mouse populations.
Interpretation: Our results highlight functional enrichments of vesicular trafficking, ion transport/homeostasis and
oxidative stress genes showing higher expression in the resistant neurons of the SNpc dorsal tier. Furthermore, the
comparison of gene expression variation in human and mouse SNpc populations strongly argues for the need of
human-focused omics studies.
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Parkinson disease (PD) results primarily from the loss ofdopaminergic (DA) neurons from the substantia nigra
pars compacta (SNpc), which is associated with both dis-
ease severity and duration.1 Currently, there are no
therapeutic approaches that would slow down or stop
these neurons from dying. The development of such
disease-modifying drugs will most likely only stem from
understanding the molecular mechanisms underlying neu-
rodegeneration in the human brain. Interestingly, not all
DA neurons in SNpc are equally affected in PD, and sev-
eral studies comparing neuronal densities between PD
patients and healthy controls have shown that the ventral
tier neurons are most susceptible to cell loss, whereas the
dorsal tier neurons remain rather resistant in the early stages
of PD.2–5 The cell loss has been described to show a selective,
temporospatial progression spreading from caudal to rostral,
lateral to medial, and ventral to dorsal pattern.2 Thus, under-
standing the distinct molecular profiles of DA neurons from
these different anatomic regions could help us to understand
why certain neurons are more vulnerable than others. More-
over, therapeutic strategies aimed at modulating specific mol-
ecules in the vulnerable/resistant subtypes could protect
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against the progressive motor symptoms associated with the
loss of DA neurons.
DNA microarrays have been the most frequently
used technique by which numerous gene expression stud-
ies have compared the postmortem brain tissue of PD
patients to healthy controls, with varying results (see Zheng
et al6 for meta-analysis). The majority of these studies have,
however, used SNpc bulk tissue, where the subpopulations
are not identified and the cellular composition is affected by
the neurodegenerative process itself, including reactive
astrogliosis and microglial activation. Their weakness is that
they ultimately focus on downstream consequences of the
disease process, rather than the underlying causes. Analysis
of cell-type–specific gene expression is possible with laser
capture microscopy that allows the isolation of precise neu-
ronal populations from the tissue.7 However, dissecting the
rare surviving DA SNpc neurons remaining in end-stage
PD8–10 may only select cells more resistant to the disease
process rather than revealing clues to the initial neurodegen-
erative mechanisms. Several studies have also compared
transcriptomic profiles of SNpc and ventral tegmental area
(VTA) in rodents,11–13 but how they relate to human gene
expression is unknown. Up to 6 molecularly distinct sub-
populations of SNpc and VTA were identified in mice
by single-cell gene-expression profiling using microfluidic
dynamic array on fluorescence-activated cell sorting
(FACS)-sorted midbrain DA cells.14 Recently, these
mouse subpopulations were also confirmed by RNA-
sequencing (RNA-seq),15 which is superior to micro-
arrays in both sensitivity and coverage.16
In the present study, for the first time in humans,
we compared the RNA-seq–derived transcriptomes of laser
capture microdissected (LCM) ventral (vulnerable) and
dorsal (resistant) tier neurons of the SNpc from healthy
individuals, to gain insight into the intrinsic differences
between these neuronal populations that could explain
their differential vulnerability in disease. Understanding
the molecular complexity of healthy midbrain DA neurons
will help uncover novel candidates for a new generation of
targeted therapeutic approaches to PD.
Subjects and Methods
Sample Collection and Preparation
We extracted RNA from the frozen midbrain of ~30 healthy
controls obtained from the Oxford MRC Control Brain Bank.
South Central–Oxford C Research Ethics Committee approved
the study (ethical license REC15/SC/0639). The RNA integrity
number (RIN) was analyzed in these samples using Bioanalyzer
(Agilent Technologies, Santa Clara, CA) and ranged between 6.6
and 9.2. Only 7 healthy controls with the highest RIN scores (≥8)
were selected for the further analysis. The mean age at death in
these 7 healthy controls (2 female, 5 male) was 70.7  12.3 years
(range = 56–93 years). Briefly, 10μm-thick sections of the frozen
midbrain were cut at the level of the 3rd nerve, dehydrated in
ethanol series, and stained with cresyl violet in strictly RNA-free
conditions. Single neuromelanized neurons were isolated from sep-
arate, nonoverlapping ventral and dorsal tiers of SNpc using ana-
tomic criteria and harvested from the stained cryosections by using
a PALM Robot–Microbeam system (Carl Zeiss, Oberkochen,
Germany; Fig 1).
RNA Extraction and Sequencing Processing
In 7 healthy controls, the total RNA was extracted from ~100
pooled LCM neurons from each tier using PicoPure RNA isolation
Kit (Arcturus, Mountain View, CA) with DNAse digestion step
(RNAse-Free DNAse Set; QIAGEN, Hilden, Germany). The
cDNA was prepared for the sequencing using the SMARTer Kit
(Clontech Laboratories, Mountain View, CA). A total of 14 sam-
ples, 2 from each tier of 7 healthy controls, were sequenced
(HiSeq4000 75bp paired-end) across 2 lanes. The resulting reads
were mapped to cDNA sequences from Homo sapiens GRCh38
release 85 available through the Ensembl FTP site (ftp://ftp.
ensembl.org/pub/). Kallisto version 0.42.4 was used to create an
index and estimate counts and transcript abundances; default
parameters were used except for the number of bootstraps, which
was set to 100.17 Finally, the tximport function in R was used to
summarize transcript abundances for all protein-coding genes.
Differential Expression
We used removal of unwanted variance (RUV) analysis to iden-
tify unwanted sources of variation.18 The first factor identified
by RUV was found across a set of 1,000 empirical control genes
and was found to be strongly correlated with the RIN score
(r = 0.956). We incorporated the first factor identified into the
model to test for differential expression between ventral and dor-
sal neurons using DESeq2.19 The model also considered the ori-
gin of the samples (ie, brain donor). Default filtering option was
set up, and those genes with either a lower number of counts or
outliers were filtered out. After filtering, 14,033 remained, and
those were used as our background gene population for further
analysis. Genes with a false discovery rate (FDR) < 0.05 were
considered differentially expressed.
TaqMan Reverse Transcribed Polymerase Chain
Reaction Assay Validation
About 100 SNpc neurons were LCM in triplicates from each tier
from the same healthy controls used for the RNA-seq analysis.
The total RNA was extracted using PicoPureTM RNA Isolation
Kit (Applied Biosystems, Foster City, CA) from 3 LCM prepara-
tions for each tier per case and pooled during elution phase. This
step was carried out to gain at least ~50ng of RNA, which was
then reverse transcribed using SuperScript ViLO cDNA synthesis
kit (Invitrogen, Carlsbad, CA). The obtained cDNA was assayed
on a Rotor-Gene Q Real-Time PCR System (QIAGEN) using
TaqMan Gene Expression Assays (Life Technologies, Carlsbad,
CA) by following standard protocols (Table). Reactions were per-
formed in duplicates using the FAM dye-labeled assay. No-
template controls were run to determine any contamination.
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Amplification for TaqMan probes reactions was performed in a
20μl reaction volume, using 10μl TaqMan Universal Master Mix
2X (Applied Biosystems), 2μl cDNA, and 1μl TaqMan Probe
20x. The comparative delta Ct method (also known as the
2-ΔΔCt method) was used to calculate the relative fold change
in gene expression. Data were normalized to housekeeping genes
(GAPDH and B2M) and gene expression in the ventral tier of
SNpc (used as control = 1).
Immunohistochemistry and Immunoblotting
Six-micrometer-thick sections of the midbrain depicting SNpc
on the level of the 3rd nerve were cut from the age-matched
healthy controls (n = 5) and processed for immunohistochemis-
try. Following antigen retrieval with autoclave at 120C for
10 minutes in citric buffer pH 6.0, endogenous peroxidase activ-
ity was eliminated with treatment with 3% H2O2 (in phosphate-
buffered saline) and PCP4, BAB3B, and HCN1 antibodies
(dilution 1:500, see above for details) incubated overnight at
4C. For detection, the REAL EnVision Detection System
(Dako, Carpinteria, CA) was used, with diaminobenzidine as
chromogen.
Two 2mm-diameter punctures were taken from the frozen
SN, 1 from the ventral and 1 from the dorsal tier, from the same
healthy controls used for the RNA-seq analysis. In addition, we
dissected 2mm-diameter punctures from the dorsal SNpc from 3 cases
with incidental Lewy body disease (with Braak PD stages I–III) and
3 PD patients (with Braak PD stages V–VI).20 Tissue was homoge-
nized in lysis buffer (5mM hydroxyethylpiperazine ethane sulfonic
acid, pH 7.4; 320mM sucrose; 1mM ethylenediaminetetraacetic acid;
0.1% sodium dodecyl sulfate; and protease inhibitors and phosphatase
inhibitors [Roche, Basel, Switzerland]) to 6% wt/vol. Following incu-
bation on ice for 30 minutes, the homogenates were spun at
5,000rpm for 10minutes at 4C. The total protein amount was deter-
mined using the BCA Protein Quantification Kit (Abcam,
FIGURE 1: Protocol of workflow and quality control. (A) Protocol of workflow: from each healthy control donor, approximately
~100 neurons from the ventral (Ve) and dorsal (Do) tier of the substantia nigra (SN) were laser capture microdissected (LCM).
Cells from 1 tier in each donor were pooled, RNA was extracted, and cDNA was obtained and prepared for sequencing, allowing
us to compare the gene expression in vulnerable versus resistant neuronal populations and finally to perform functional analysis.
3rd = oculomotor nerve; GO = Gene Ontology; MP = Mammalian Phenotype; PL = pars lateralis. (B) Mapping rates as the
percentage of reads mapping protein-coding genes in each of the 14 available samples. The dashed line at 30% has been drawn
to highlight samples with particularly lower mapping rates (healthy control [HC]1, 3, and 4 were excluded from further analysis).
(C) Library complexity shown as the cumulative proportion of the library for the top 100 most expressed features/genes in each
sample. (D) First 2 principal components (PC), which together explain ~45% of the variance. Label colors reflect the origin of the
samples, whereas the intensity of the dots denotes the total number of counts in each sample (darker colors represent higher
number of counts).
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Cambridge, UK) and adjusted to 2mg/ml. Brain samples were diluted
with 0.1 × sample buffer followed by 4 parts of diluted sample com-
bined with 1 part of Fluorescent Master Mix and heated at 95C for
5 minutes. The denatured samples, blocking reagent, primary anti-
bodies (PCP4, 14705-1-AP, Proteintech Group, Rosemont, IL;
RAB3B, 15774-1-AP, Proteintech Group; HCN1, GTX131334,
GeneTex, Irvine, CA, all with 1:50 dilution; and β-actin ab8224,
Abcam, 1:100 dilution), mouse and rabbit horseradish peroxidase–
conjugated secondary antibodies, and chemiluminescent substrate
were dispensed into a 384-well plate. A biotinylated ladder provided
molecular weight standards for each assay. After plate loading, the sep-
aration electrophoresis and immunodetection steps took place in the
fully automated Peggy Sue (Protein Simple, San Jose, CA) capillary
system.
Functional Enrichment Analysis
Gene Ontology (GO) annotations were obtained through
biomaRt in R from Ensembl release 85, whereas Mammalian
Phenotype (MP) annotations were retrieved from the MGI
Batch Query tool (accessed on December 16, 2016) using all
available Ensembl gene IDs from Mus musculus with 1-to-1
ortholog correspondence to H. sapiens. GO enrichment analysis
included terms with at least 50 genes in our background
population. MP enrichment analysis included all 28 major
phenotypes first, and if a major phenotypic term was signifi-
cantly enriched, we performed a second enrichment analysis
among more specific phenotypic terms (with a minimum of
20 genes in our background population). For the actual test,
we compared the number of genes assigned to each term to an
estimated expected number derived from 1,000 equally sized
random samples of genes. A p value has been estimated based
on a z score derived from the randomizations and further
adjusted for multiple testing using the Benjamini–Hochberg
method. GO terms with an FDR < 0.05 and containing at least
2 genes were deemed significantly overrepresented.
Coexpression
Based on the expression profiles across all samples available from
multiple brain structures across development in BrainSpan,21 we
calculated the coexpression between each gene pair as the Pear-
son correlation between their expression levels. The average
coexpression between all gene pairs in each subset of differen-
tially expressed genes (DEGs) was measured and compared to
10,000 equally sized random samples of genes from the back-
ground population. An estimated p value was drawn from the
randomizations by counting the number of cases in which the
average coexpression was equal to or higher than that observed
for each set of DEGs.
TABLE. Validation of Gene Expression Using TaqMan Real-Time Polymerase Chain Reaction
Gene Protein TaqMan Assay ID
GAPDH Glyceraldehyde-3-phosphate dehydrogenase Hs99999905_m1
B2M Beta-2-microglobulin Hs99999907_m1
TH Tyrosine hydroxylase Hs00165941_m1
DAT Dopamine transporter Hs00997374_m1
VMAT2 Vesicular monoamine transporter 2 Hs00996834_g1
GFAP Glial fibrillary acidic protein Hs00909233_m1
PMP22 Peripheral myelin protein 22 Hs00165556_m1
GAD1 Glutamate decarboxylase 1 Hs01065892_m1
PCP4 Purkinje cell protein 4 Hs01113637_m1
RAB3B Ras-related protein Rab-3B Hs01001137_m1
HCN1 Potassium/sodium hyperpolarization-activated
cyclic nucleotide-gated channel 1
Hs01570432_m1
SPARC Secreted protein acidic and rich in cysteine Hs00234160_m1
SNX8 Sorting nexin 8 Hs01030705_m1
MT1G Metallothionein-1G Hs01584215_g1
ANXA1 Annexin A1 Hs00167549_m1
ATP13A4 Cation-transporting ATPase 13A4 Hs01115518_m1
LYPD1 Ly6/PLAUR domain-containing protein 1 Hs00375992_m1
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Protein–Protein Interactions
A combined protein–protein interaction network was created
based on diverse resources: BioGRID 3.4 (accessed on October
13, 2016),22 HitPredict (accessed on October 20, 2016), IntAct
(accessed on October 11, 2016), STRING (accessed on
November 29, 2016, restricted to H. sapiens and experimental
scores >0), CORUM (accessed on October 11, 2016), and
Reactome (accessed on October 11, 2016). The combined net-
work reflected the presence of an interaction in any of the afore-
mentioned resources, representing a total of 20,591 genes and
1,973,967 interactions, where self-interactions were not consid-
ered. We have measured both the number of interactions and the
clustering in the combined protein–protein interaction network
among DEGs between ventral and dorsal neurons. To compare
the observed parameters to those expected by chance, we have
created 1,000 equally sized randomizations with a similar degree
distribution to set of DEGs. To accomplish this, we have
log2-transformed the degree distribution of all genes in our
background population, divided all genes into 20 bins, and
counted the number of DEGs falling in each bin, so for each
randomization an equal number of genes from each bin would
be drawn. Finally, a p value would be estimated based on the
number of cases in which the number of interactions of the clus-
tering was either equal to or higher than that observed for each
set of DEGs.
Phenotypic-Linkage Network
A phenotypic-linkage network (PLN) has been used to integrate
diverse functional sources of information into a single measure.
From coexpression based on the BrainSpan dataset, only the top
5% of the strongest correlations were taken into account for the
PLN. The combined protein–protein interaction network has
also been included, as well as similarity between shared GO
annotations, measured separately for biological processes, molec-
ular function, and cellular component.23
Results
Our study sought to reveal the intrinsic differences in gene
expression patterns in the human healthy control individuals
between the 2 neuronal populations, ventral and dorsal
SNpc, known to show selective vulnerability in PD. For this,
we compared the transcriptional profiles of ventral and dorsal
SNpc neurons obtained from the midbrain at the level of the
3rd nerve from 7 healthy brain donors. Approximately ~100
cells from each tier were LCM, followed by RNA extraction
and sequencing of each sample (see Fig 1). Samples from 3 of
7 donors were removed from further analysis, given their par-
ticularly low mapping rates and reduced library complexity.
Principal component analysis based across all sequenced sam-
ples segregated along the first component samples identified
and removed by their low quality.
Transcriptional Signature of DA Neurons
We confirmed the DA identity of our samples (Fig 2A) by
looking at the transcript levels of dopamine transporters
(VMAT and DAT), enzymes involved in the synthesis
of dopamine (TH and DDC), and transcription factors
involved in dopamine specification and maintenance
FIGURE 2: Characterization of laser capture microdissected (LCM) dopaminergic neurons. (A) Samples showed high gene
expression levels (log2[CPM + 1] (CPM means counts per million)) of dopaminergic markers including dopamine transporters,
enzymes involved in dopamine synthesis, and transcription factors necessary for dopaminergic specification, whereas ventral
tegmental area–specific markers (ADCYAP1, LPL, OTX2, and VIP) were virtually absent. The lines denote the mean and median
expression of the whole background gene population. (B) Assessment of dopamine neuron sample enrichment and purity by
reverse transcribed quantitative polymerase chain reaction in LCM substantia nigra pars compacta (SNpc) neurons in relation to
whole midbrain sections that have not been altered in terms of cellular content and therefore contain dopamine neurons and
many other cell types. The 2-ΔΔCt method shows increased expression of the dopaminergic genes DAT, TH, and VMAT2 in the
LCM SNpc neurons normalized to sections (value 1, red line), indicating dopamine neuron enrichment. A significant reduction in
expression of genes for the glial fibrillary acidic protein 1 (GFAP), peripheral myelin protein 22 (PMP22) and glutamate
decarboxylase 1 (GAD1) suggests isolation of a relatively pure population of dopamine neurons. (C) Proportion of neurons,
astrocytes, microglia, oligodendrocytes, oligodendrocyte precursor cells (OPC), and endothelial cells estimated by MuSiC, an
RNA-sequencing deconvolution method.
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(NR4A2, FOXA2, EN1). All of them were highly expressed
when compared to the average expression of all protein-
coding genes. Additionally, LMX1B and EN2 were moder-
ately expressed, whereas PITX3 was detected just below the
median of the whole gene population. Given the presence of
DA neurons in the neighboring VTA, we examined the
expression levels of genes reported to be specific to the VTA
(OTX2, ADCYAP1, and VIP) and found them to be virtually
undetectable.
By real-time quantitative polymerase chain reaction
(reverse transcribed-qPCR), the relative expression levels of
all dopamine neuron-related transcripts (TH, DAT, VMAT2)
were significantly increased in the microdissected nigral neu-
rons compared to whole midbrain sections (see Fig 2B). This
confirmed the efficiency of the LCM process in terms of its
ability to quantitatively capture the targeted DA cells. Corre-
spondingly, the expression of astroglial (GFAP), oligoden-
droglia (PMP22), and γ-aminobutyric acidergic (GABAergic;
GAD1) genes were very low, suggesting isolation of a rela-
tively pure population of dopamine neurons. Finally, the pro-
portion of brain cell types within our samples was estimated
with MuSiC,24 a recent deconvolution method for bulk
RNA-seq that we applied along with single cell gene expres-
sion data from neurons, oligodendrocytes, astrocytes,
microglia, and endothelial cells.25 This estimate supported
a very high percentage of neurons within our samples
(mean = 96.87%; see Fig 2C). No significant difference was
found between dorsal and ventral samples (p > 0.05).
DEGs between Human Ventral and Dorsal SNpc
Neurons
To obtain an unbiased set of genes with distinct patterns of
expression between human ventral and dorsal SNpc neurons,
we considered 14,033 protein-coding genes remaining fol-
lowing the removal of outliers and genes with low expression
(see Subjects and Methods). We first applied RUV analysis18
to remove the first factor of variation, which was associated
with RIN score (Pearson correlation r = 0.956). Despite
application of RUV, the principal drivers of variation in the
data continued to be associated with technical and sample
source (genotype) variation rather than anatomical localiza-
tion. Nonetheless, ventral and dorsal samples segregated
along the 5th component, which accounts for 2.44% of the
gene expression variance (Fig 3A). We then applied DESeq2
accounting for the origin (donor) of each pair of ventral/dor-
sal samples. In total, 106 genes were detected as differentially
expressed (FDR < 0.05), 58 of which were higher in the dor-
sal/resistant neurons, whereas the remaining 48 were higher
in the ventral/vulnerable neurons (see Fig 3B, C). We tested
whether the number of DEGs was higher than expected by
chance by permuting label groups (dorsal/ventral) of samples
followed by differential gene expression analysis. Among
these permutations, the number of genes detected as differen-
tially expressed was always smaller than the number obtained
when the correct labels were assigned (observed = 106, per-
mutations = 41, 67, and 25), confirming that the number of
DEGs identified between tiers was higher than expected by
chance.
Validation with RT-qPCR and Further Protein
Analyses of the Top DEGs
Using the 2-ΔΔCt method to determine the fold differ-
ences of relative gene expression between dorsal and ven-
tral SNpc tiers in our top 10 DEGs largely confirmed the
results from the RNA-seq analysis (Fig 4). As predicted,
RT-qPCR analysis found PCP4 highly increased in dorsal
versus ventral SNpc neurons, followed by RAB3B, HCN1,
SPARC, SNX8, and MT1G, whereas the expression of
ATP13A4 and LYPD1 were decreased. However, we could
not confirm by RT-qPCR the dorsal upregulation of GFAP
and ANXA1 found by RNA-seq. The PCP4 (Purkinje cell
protein) immunohistochemistry showed extensive labeling
of the processes in the SNpc and pars reticulata. However,
we could not detect any cytoplasmic staining of the
pigmented DA SNpc neurons. The RAB3B expression was
also rather diffuse throughout the midbrain, whereas after
trialing several HCN1 antibodies we could not detect any
reliable staining in our postmortem brain tissue. Using
automated quantitative Western blot, we further examined
the protein levels of our top 3 DEGs in dorsal versus ven-
tral SNpc tier (in 2mm-diameter punctures). We found
that PCP4 and HCN1 appeared to have slightly higher
protein levels in the dorsal SNpc tier, similarly to their gene
expression, whereas RAB3B showed higher protein levels in
the ventral SNpc, in contrast to the mRNA level findings.
However, the variability between punctured samples was
high, and none of the differences reached statistical signifi-
cance. Furthermore, we examined protein expression levels
of the same 3 proteins in dorsal SNpc during the pathologi-
cal progression of PD and showed that HCN1 protein
expression significantly increased with Braak PD stages
(analysis of variance, p = 0.03). The PCP4 levels appeared
to increase at later Braak stages (V–VI), whereas RAB3B
levels were more stable throughout the disease progression.
Insights from Functional Analysis
As a general approach, we looked for evidence of func-
tional associations among each group of upregulated genes
(ventral/vulnerable and dorsal/resistant neurons), while
controlling for the total set of genes expressed across the
sampled cells. Gene pairs with coordinated expression patterns
are more likely to be involved in a similar function,26,27 and
so we determined the coordinated expression pattern for each
pair of DEGs with the brain across different structures and
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FIGURE 3: Gene expression differences between human vulnerable and resistant substantia nigra pars compacta (SNpc) neurons.
(A) Principal component (PC) 5 after removal of unwanted variance factor 1 separates ventral and dorsal SNpc neurons and
explains ~2.44% of the variance. HC = healthy control. (B, C) Expression patterns for genes detected differentially expressed
between tiers (false discovery rate < 0.05) shown for (B) genes with significantly higher expression in ventral/vulnerable SNpc
and (C) genes with significantly higher expression in dorsal/resistant SNpc. Gene expression is given in counts per million (CPM)
and scaled by gene.
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development using the BrainSpan Atlas of the Developing
Human Brain.21 We found that the average coexpression
between increased genes in the dorsal/resistant neurons is
higher than we would expect from equally sized random sam-
ples of genes (empirical p = 0.0005), supporting convergent
functionality. However, genes increased in the ventral/vulner-
able neurons are not significantly coexpressed across brain tis-
sues (empirical p = 0.2762).
Using a comprehensive integrated functional genomics
approach, termed a PLN, we looked for evidence of functional
convergence among DEGs. A PLN combines multiple sources
of functional information (GO annotations, coexpression, and
protein–protein interactions) into a single weighted measure of
gene functional relatedness between all pairs of genes.23
To measure functional convergence, we compared the sum of
the weighted edges between gene pairs in the PLN. We
observed higher than expected functional convergence between
genes increased in the dorsal/resistant neurons (p < 0.001;
Fig 5A), whereas genes increased in the ventral/vulnerable neu-
rons did not functionally converge more than expected by
chance (p = 0.594; see Fig 5B). When considering the struc-
ture of links among DEGs within the PLN by calculating the
global clustering and in comparison to random samples of
genes, we noticed a higher than expected clustering for both
increased genes in the dorsal/resistant (p = 0.033) and in the
ventral/vulnerable neurons (p = 0.004). Overall, genes
increased in the dorsal/resistant neurons have stronger links
and tend to share links with neighboring genes within the
FIGURE 4: Reverse transcribed quantitative polymerase chain reaction validation and protein analysis of top differentially
expressed genes. (A) Using the 2-ΔΔCt method, increased gene expression of PCP4, RAB3B, HCN1, SPARC, SNX8, and MT1G was
found in the dorsal substantia nigra pars compacta (SNpc) tier in relation to the ventral SNpc tier (marked as value 1, red line).
ATP13A4 and LYPD1 were downregulated in dorsal SNpc, whereas GFAP and ANXA1 showed highly variable expression between
the SNpc tiers. (B, C) PCP4 immunohistochemistry strongly labeled the cell bodies and processes of the cerebellar Purkinje cells
(B) and the processes around SNpc and SN pars reticulata (C), leaving devoid of the soma of the pigmented dopaminergic neurons
of the SNpc (arrows). Asterisks in inserts show the position of the figures at ×200 magnification. (D, E) Immunoblots and
histograms (mean  standard error of the mean) showing relative protein expression of PCP4, RAB3B, and HCN1 in the ventral
versus dorsal tiers of SNpc (D) and in the dorsal SNpc between different Braak stages (E). The results are expressed as the ratio of
target protein/β-actin (internal control) in each group. AUC = area under the curve; HC = healthy controls.
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PLN, whereas genes increased in the ventral/vulnerable neu-
rons have weaker links but still share common neighbors
within the PLN. Taken together, these network results provide
evidence of functional clustering and thus shared functionality.
Among genes higher in the dorsal/resistant neurons, we
found significantly overrepresented GO Biological Process
terms receptor mediated endocytosis (fold overrepresentation
[FOR] = 8.62), calcium ion homeostasis (FOR = 7.49), potas-
sium ion transport (FOR = 7.43) regulation of cell proliferation
(FOR = 7.56), cell surface receptor signalling (FOR = 4.53), cen-
tral nervous system development (FOR = 7.69), cellular response
to TNF (FOR = 8.62), and insulin stimulus (FOR = 7.66; see
Fig 5C). By contrast, genes higher in ventral/vulnerable neu-
rons were overrepresented in processes such as the negative reg-
ulation of cell migration (FOR = 14.15), canonical Wnt
signalling (FOR = 11.49), and positive regulation of proteasomal
ubiquitin dependent protein catabolic process (FOR = 9.47; see
Fig 5D). The complete GO enrichment analysis results are
FIGURE 5: Functional convergence among increased genes in neuronal populations of each substantia nigra pars compacta
(SNpc) tier. The phenotypic linkage network integrates diverse sources of functional association (gene ontology, coexpression,
and protein–protein interactions) into a single measure of functional similarity between genes, where nodes represent genes and
edges denote the weighted functional association between them. (A, B) Phenotypic linkage subnetwork for all increased genes
(A) in the dorsal/resistant neurons and (B) in the ventral/vulnerable neurons. (C, D) Overrepresented gene ontology annotations
(false discovery rate [FDR] < 0.05) for (C) genes with higher expression in dorsal/resistant SNpc and (D) for genes with higher
expression in ventral/resistant SNpc. Dashed lines indicate an FDR threshold of 0.05.
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given in the Supplementary Table. Overrepresentation of a
unique set of specific processes was found among genes
upregulated in neurons from each tier.
Additionally, we looked for any unusually overrepre-
sented phenotypes among the unique (1:1) orthologues of
these genes that had been experimentally disrupted in the
mouse. Among genes increased in the dorsal/resistant
neurons, we found 4 phenotypic classes overrepresented
(Fig 6A), including Nervous System (FOR = 1.84) and
Homeostasis/Metabolism (FOR = 1.79). Examining more
specific terms within the Nervous System category (see Fig 6B)
revealed an overrepresentation of genes whose unique mouse
orthologue’s disruption yields a decreased nerve conduction
velocity (FOR = 22.38), abnormal myelination (FOR = 9.64),
and axon degeneration (FOR = 7.75). No mouse orthologue
phenotypic associations were found among genes increased in
the ventral/vulnerable neurons.
Links to Known PD Genes
The differential susceptibility to neurodegeneration between
neurons from the ventral and dorsal tiers of SNpc led us to
search for genes (and interactions) linked to the disease in
the DEG sets. We examined the identified DEGs between
the 2 neuronal populations for genes associated with familial
PD, or those genes located within regions of high linkage
disequilibrium (LD) to single nucleotide polymorphisms
FIGURE 6: Mammalian Phenotype annotation and overrepresentation analysis for increased genes in the dorsal/resistant
substantia nigra pars compacta (SNpc) neurons. (A) Genes with higher expression in dorsal/resistant neurons annotated to at
least 1 overrepresented Mammalian Phenotype class (false discovery rate < 0.05). (B) Specific nervous system phenotypes
overrepresented in genes with higher expression in dorsal/resistant SNpc neurons. (C) Specific homeostasis- or metabolism-
associated phenotypes overrepresented in genes with higher expression in dorsal/resistant SNpc neurons. CNS = central
nervous system.
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FIGURE 7: Human gene expression patterns in ventral and dorsal substantia nigra pars compacta (SNpc) neurons. (A) Genes that
were expected to have higher expression in the ventral tier of SNpc according to previous mouse data also included genes
(SATB1, ANXA1, FGF1, and PTPN5) that showed higher expression in the dorsal tier of SNpc in humans. (B) Likewise, genes that
were expected to have higher expression in the dorsal tier of SNpc also included LYDP1, with higher expression in the ventral
tier of SNpc in humans. CPM means Counts per million.
June 2020 863
Monzón-Sandoval et al: Selective Vulnerability and PD
(SNPs) associated with the disease by recent PD meta-ana-
lyses.28 None of the DEGs was among the familial PD
genes or in high LD to associated genome-wide association
study (GWAS) SNPs. Although we did identify protein–
protein interactions between DEGs and PD-associated
genes, the number of interactions was no more than we
would expect by chance when compared to random genes
expressed in these neuron types.
Human to Mouse Gene Expression Comparison
Mouse FACS-sorted midbrain DA neurons have been pre-
viously distinguished based on the transcriptional profiling
with an array including genes reported to be differentially
expressed between SN and VTA, validated DA markers,
and housekeeping genes.14 Two DA neuron clusters identi-
fied by Poulin et al14 had similar expression profiles to
SNpc (DA1A-1B) and VTA (DA2A-2D), and further sub-
division into DA1A and DA1B subtypes corresponded to
the ventral and dorsal tiers of human SNpc, respectively.
Furthermore, recently mouse DA neurons were classified
into 5 distinct subpopulations DA-SNC and DA-VTA1–4
using single-cell RNA-seq.15 As the DA-VTA1 subgroup
in La Manno et al15 was positioned more toward the dorsal
SNpc per Allen Mouse Brain Atlas, we considered this
comparable to our human dorsal SNpc and the mouse
DA-SNC subgroup to be comparable to our human ventral
SNpc. Thus, for gene markers reported to be different
between DA1A/DA-SNC and DA1B/DA-VTA1 in mice,
we looked at the relative expression in our human data.
Some genes reported to have higher expression levels in anal-
ogous ventral SNpc mouse subpopulations (ALDH1A1,
SNCA, SOX6, GRIK1, and NOSTRIN) showed similar tier-
specific directionality in humans (Fig 7A), although none of
the human genes reached statistical significance. Similarly,
CHRNA4, FJX1, FOXA2, CALB1, GFRA2, and POU3F1,
with higher reported expression in analogous dorsal SNpc
mouse subpopulations, also tended to have higher levels in
our human dorsal SNpc neurons (see Fig 7B). However, we
also identified genes with opposite trends between the spe-
cies. For example, SATB1, FGF1, PTPN5, and ANXA1
were unexpectedly more expressed in the human dorsal
SNpc neurons and LYPD1 in the ventral SNpc neurons,
despite the opposite direction having been reported in
mice.14,15 Nevertheless, from all the genes compared
between humans and mice, only 2 (ANXA1 and LYPD1)
were deemed differentially expressed in our human analysis
(FDR < 0.05).
Discussion
Our study focused on comparing the RNA-seq trans-
criptomic profiles of the ventral and dorsal tiers of SNpc
neurons in healthy individuals as we sought to identify
intrinsic differences between the 2 neuronal populations
that could inform on their differential vulnerability in the
context of PD. Performing the comparison among healthy
individuals aids in capturing similar numbers of neurons
from both tiers; furthermore, the selection of cells is not
biased toward only surviving neurons, as might occur if
the same neuronal populations were compared between
PD patients and healthy controls. LCM neurons were
selected on the basis of their pigmentation and anatomic
localization and expressed very high levels of VMAT,
DAT, TH, and DDC genes, reflecting a DA profile. No
significant differences in these DA marker gene levels were
found between neurons from the ventral and dorsal tiers
of the SNpc, supporting our aim to capture and compare
similar numbers of DA neurons. It is also important that
the expression levels of genes reported to be specific to the
VTA (OTX2, ADCYAP1, and VIP) were virtually
undetectable, reflecting the absence of VTA DA neurons
in our samples. In addition to RNA-seq, we validated the
level of enrichment and purity of dopamine neurons by
RT-qPCR, assessing the dopamine neuron and glial/
GABAergic-specific gene expression in the LCM cells ver-
sus whole midbrain sections. However, despite the careful
execution of LCM, "contamination" with non-neuronal
transcription signals (eg, GFAP, PMP22) can occur, but
this is at much lower levels than what is found in the bulk
tissue. However, we also confirmed a very high neuronal
proportion of our sample by MuSiC,24,25 a recent RNA-
seq deconvolution method for bulk tissue.
We found 106 DEGs between neuronal populations
from the ventral and dorsal tier (FDR < 0.05),
corresponding to 0.75% of our background gene popula-
tion and 0.5% of all protein-coding genes. We consider
that some genes increased in the dorsal neurons (n = 58)
could provide a protective effect in PD, and/or conversely,
genes increased in the ventral neurons (n = 48) might con-
fer higher vulnerability. Of particular interest in the con-
text of neurodegeneration and PD are those genes that
show abnormal phenotypes of the nervous system when
the corresponding mice ortholog is disrupted, but also
those directly involved in metabolic processes, given the
high energy demand of DA neurons. Our study revealed a
coherent group of genes increased among the dorsal/resis-
tant neurons with functional convergence in phenotypes
associated with neural function and homeostasis, many of
which may be relevant to the possible protective effect of
these neuronal populations in PD (see below). These
genes demonstrated more coordinated temporal and spa-
tial expression patterns across the human brain, their pro-
tein products were more likely to interact, and they
presented stronger functional associations with each other
than expected by chance in an integrative functional gene
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network. In contrast, genes increased in the more vulnera-
ble ventral SN neurons did not exhibit strong evidence for
shared functionality.
Vesicular Trafficking
Genetic discoveries have brought defects in vesicle traffick-
ing to the forefront of potential pathogenic players in
PD.29 The Rab protein family enriched in neuronal syn-
aptic vesicles plays a key regulatory role in vesicle traffick-
ing. Rabs have been shown to be closely associated with
α-synuclein (aSyn)-mediated pathological processes but
also to interact with many PD-related genes, and thus
they could plausibly be regarded as novel biomarkers or
therapeutic targets.28 We found 2 members of this family
increased among the dorsal/resistant SNpc neurons:
RAB3B and RAB13. The subfamily of RAB3 proteins in
particular has been reported to have stronger gene expres-
sion in the relatively spared VTA than in the SN neurons
in a human brain and elevated protein expression in the
projections of the VTA in the ventromedial striatum of
the rat.11,30 When overexpressed in rat SN DA neurons,
it increases the number and size of synaptic vesicles in the
DA presynaptic terminals and dopamine content in the
striatum.30 When RAB3B is overexpressed, it also shows a
protective effect in DA neurons treated with oxidative
stressor 6-hydroxydopamine and the proteasome inhibitor.
Conversely, when RAB3B is knocked down by siRNA, DA
neurons show an increased vulnerability to both toxins.29 A
protective effect of RAB13 on the other hand involves the
clearance of aSyn inclusions through endocytic recycling
and rescued aSyn-induced toxicity.31 Furthermore, several
members of the RAB family including RAB3 get phosphor-
ylated by LRRK2,32 whereas RAB13 phosphorylation
occurs in response to PINK1 activation.33
In addition to Rab genes, SNX8 (sorting nexin 8)
and ANXA1 (annexin A1), genes involved in intracellular traf-
ficking, were higher among dorsal/resistant SNpc neurons.
SNX8 is a key element of retromer-mediated endosomal pro-
tein sorting, also emerging as important cellular machinery in
PD.34 ANXA1 is a key mediator of endoplasmic reticulum
(ER) contact sites required for the ER-derived cholesterol
transport to endosomes.35
Ion Transport and Homeostasis
Another shared feature of vulnerable SNpc neurons is their dis-
tinctive physiology of autonomous pacemaking activity that
mainly relies on Ca2+ channels.36 However, when these
channels are knocked down, a reversal to a more “juvenile”
pacemaking activity dependent on Na+ and hyperpolarization-
activated cyclic nucleotide gated (HCN) potassium channels
can protect neurons from methylphenyltetrahydropyridine
(MPTP)-induced cell death.37 There are 4 HCN genes in
mammals (HCN1–HCN4), each of them showing different
biophysical properties. Although HCN4 has been reported to
have higher transcript abundance in rodent SNpc neurons,38
we identified higher HCN1 expression in dorsal/resistant
SNpc neurons in humans.HCN1 has been found to be higher
with age in the MitoPark mouse, a genetic model of PD with
disrupted mitochondrial function, perhaps as a compensatory
effect to sustain firing rates and neural function.39 Our study
also identified the expression of SLC4A4 (Na+-coupled acid-
base transporter), EDN1 (endothelin-1),40 and PCP4
(Purkinje cell protein 4) as higher in the dorsal SNpc neurons,
all genes that maintain Ca2+ homeostasis and thus may be pro-
tective. PCP4 (also known as PEP-19) in particular regulates
Ca2+ binding to calmodulin, and the levels of transcript and
protein of PEP-19 are reduced in striatum of the MPTP
mouse model of PD.41 In addition, we found higher expres-
sion of ATP13A4, cation-transporting, P5-type adenosine
triphosphatase, among the ventral SNpc neurons. Mutations
in this gene have been implicated mainly in the developmental
disorders and have been shown to reduce calcium transport
in vitro.42 The related family gene ATP13A2 is actually
PARK9 locus, linked to autosomal recessive familial
parkinsonism,43 but we found no differences in its expression
between the SNpc tiers.
Oxidative Stress
Although oxidative stress processes were not directly overrep-
resented among the increased genes, genes related to oxida-
tion such as HBB and HBA2 (hemoglobin subunit β/α2)
were higher among the dorsal/resistant SNpc neurons. Inter-
estingly, apart from binding to O2 and CO2 in blood, hemo-
globin is also present in SNpc DA neurons in mice and
humans. It may act as storage for oxygen, providing homeo-
static mechanisms for SNpc DA neurons that have an
exceptionally high energy requirement.44 Furthermore,
double-labeling immunofluorescence has shown reduced
levels of hemoglobin specifically in the neurons with aSyn-
immunopositive Lewy bodies.45 In addition, the expression
of MT1G (metallothioneins), a free radical scavenger, was
also higher among the dorsal SNpc neurons and has been
shown to provide a neuroprotective effect in the rotenone
mouse model of PD.46 The increased SPARC (secreted pro-
tein acidic and rich in cysteine) gene in dorsal SNpc neurons
was recently linked to PD by in silico study that identified
novel proteins involved in Cu and Fe metabolism.47
One important goal of our human-specific trans-
criptomic profiling of selectively vulnerable SNpc populations
was to analyze the possible links to known PD genes. Unex-
pectedly, we did not find any overlap between our DEG and
PD familial genes or those genes located within regions of high
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LD to SNPs associated with the disease by recent PD meta-
analyses.28 However, we did find 4 increased genes that have
been identified as GWAS hits of modest significance for spo-
radic PD by other smaller studies—3 higher among the dorsal
SNpc neurons: MMRN2 (multimerin 2),48 ANXA1,49 and
B2M (beta-2-microglobulin)50; and 1 higher among the ven-
tral SNpc neurons: AGTR (angiotensin II receptor type 1).51
Although RNA-seq is a very powerful technique,
some technical artifacts may be present in the data (eg,
starting concentrations or cDNA quality), and validation
with an independent technique is therefore advisable using
different biological replicates from the same population.
The RT-qPCR validation of our top 10 DEGs largely
confirmed the RNA-seq results, but not always; for exam-
ple, GFAP, being one of the most abundant proteins of
the brain, is likely to be a result of contamination by the
LCM process itself. However, 3 of our DEGs (PCP4,
BAB3B, and HCN1) showed clearly higher gene expres-
sion in the dorsal versus ventral SNpc neurons. Thus, we
wanted to further examine their protein levels, although it
is important to note that these analyses are entirely obser-
vational rather than validating our RNA-seq results as
such. The relationship between mRNA and protein is
complex, as the steady-state transcript abundances only
partially predict the protein levels, and processes down-
stream of transcription play a strong regulatory role.52
Although mass spectrometry–based proteomic analysis of
neurons isolated from postmortem human brain by LCM
is possible,53 this was beyond the scope of our current
study. Therefore, we examined the protein levels in situ
using immunohistochemistry but also immunoblotting the
2mm punctures from both ventral and dorsal SNpc tiers.
Furthermore, we were interested to see whether we could
observe any changes in the protein levels during the pro-
gression of PD pathology (ie, in different Braak stages).
The PCP4 immunohistochemistry showed extensive
labeling of the processes throughout the SNpc devoid of
any clear cytoplasmic staining of the pigmented DA SNpc
neurons. In the human brain, PCP4 immunoreactivity is
mainly found in the processes of basal ganglia and sub-
stantia nigra, and in the cell bodies of thalamic nuclei,
dentate gyrus, and Purkinje cells.54 Thus, our RNA-seq
signal with PCP4 likely originates from the processes that
are inevitably included in the LCM procedure, the epitope
of our antibody does not recognize PCP4 in the cell body
(eg, similar to neurofilament staining), or increased
mRNA does not manifest as protein change detectable
with immunohistochemistry. Similarly, the RAB3B pro-
teins30 are mainly enriched in the presynaptic terminals,
and we detected rather diffuse reactivity throughout the
midbrain. Although the variability between the 2mm
puncture samples was high, PCP4 and HCN1 appeared
to have slightly higher protein levels in the dorsal SNpc,
similar to their gene expression. On the other hand,
RAB3B showed a tendency to higher protein levels in the
ventral SNpc, in contrast to its mRNA, highlighting fur-
ther that mRNA and protein are not necessarily congru-
ent. Finally, we showed that HCN1 protein expression in
the dorsal SNpc increased with progression of PD pathol-
ogy, suggesting the possibility of a compensatory effect
similar to that observed in the MitoPark mouse,39 but this
needs further investigation.
Our comparisons of gene expression variation in
human ventral and dorsal SNpc DA neurons to analo-
gous groups of DA1A/DA-SNC and DA1B/DA-VTA1
characterized in mice14,15 identified several genes with
similar orientation in the expression pattern across the
tiers. However, none of these genes was found to be sig-
nificantly differentially expressed in humans. In our
study, only LYPD1 and ANXA1 showed significant dif-
ferences in expression, and they were increased in the
opposite direction across the tiers between the 2 species.
Such differences found between humans and mice justify
the importance of a human-focused understanding of the
intrinsic difference between the different populations of
DA neurons.
This study underscores the value of human postmor-
tem transcriptome studies, which to date are hampered by
the scarcity of suitable tissue resources. Future studies
would benefit from higher sample numbers and single-
nuclei sequencing instead of LCM to avoid cell type con-
tamination issues. However, nuclei sequencing is limited
to capturing only a fraction of the cellular mRNA popula-
tion. Human-focused omics atlases such as that described
here provide important references for future research.
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